Cynomolgus studies with lead TRACTrs have demonstrated safety proof-of-concept to support IND-enabling development activities. Our lead TRACTr product candidates are designed to target PSMA, EGFR, and TROP2. Each of these tumor targets are clinically validated and implicated in solid tumors with high prevalence. We are also applying our proprietary technology to develop a costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28 designed to further enhance the anti-tumor activity of T cells, which we believe has the potential to be used as a single-agent or in combination with our current TRACTr pipeline.
|Program||Targets||Initial Indications||Discovery||IND-Enabling||Phase 1||Phase 2/3|
|TROP2-TRACTr||TROP2xCD3||TNBC, UC, NSCLC|
|Costim bispecific||PD-L1xCD28||Solid Tumors|